Hamlet BioPharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
For the nine months, revenue was SEK 0.029971 million. Net loss was SEK 30.28 million compared to SEK 17.31 million a year ago. Basic loss per share from continuing operations was SEK 0.1716 compared to SEK 0.1566 a year ago.